In:
Liver International, Wiley, Vol. 38, No. 1 ( 2018-01), p. 155-163
Kurzfassung:
Non‐alcoholic fatty liver disease ( NAFLD ) is a chronic liver disorder, tightly associated with obesity. The histological spectrum of the disease ranges from simple steatosis to steatohepatitis, with different stages of fibrosis, and fibrosis stage is the most significant predictor of mortality in NAFLD . Liver biopsy continues to be the gold standard for its diagnosis and reliable non‐invasive diagnostic tools are unavailable. We investigated the accuracy of candidate proteins, identified by an in silico approach, as biomarkers for diagnosis of fibrosis. Methods Seventy‐one morbidly obese ( MO ) subjects with biopsy‐proven NAFLD were enrolled, and the cohort was subdivided according to minimal (F0/F1) or moderate (F2/F3) fibrosis. The plasmatic level of CD 44 antigen ( CD 44), secreted protein acidic and rich in cysteine ( SPARC ), epidermal growth factor receptor ( EGFR ) and insulin‐like growth factor 2 ( IGF 2) were determined by ELISA . Significant associations between plasmatic levels and histological fibrosis were determined by correlation analysis and the diagnostic accuracy by the area under receiver operating characteristic curves ( AUROC ). Results Eighty‐two percentage of the subjects had F0/F1 and 18% with F2/F3 fibrosis. Plasmatic levels of IGF 2, EGFR and their ratio ( EGFR / IGF 2) were associated with liver fibrosis, correlating inversely for IGF 2 ( P 〈 .006) and directly ( P 〈 .018; P 〈 .0001) for EGFR and EGFR / IGF 2 respectively. The IGF 2 marker had the best diagnostic accuracy for moderate fibrosis ( AUROC 0.83), followed by EGFR / IGF 2 ratio ( AUROC 0.79) and EGFR ( AUROC 0.71). Conclusions Our study supports the potential utility of IGF 2 and EGFR as non‐invasive diagnostic biomarkers for liver fibrosis in morbidly obese subjects.
Materialart:
Online-Ressource
ISSN:
1478-3223
,
1478-3231
DOI:
10.1111/liv.2018.38.issue-1
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2018
ZDB Id:
2124684-1
Permalink